Keith M. Gregg

2.6k total citations · 1 hit paper
21 papers, 1.8k citations indexed

About

Keith M. Gregg is a scholar working on Physiology, Psychiatry and Mental health and Cognitive Neuroscience. According to data from OpenAlex, Keith M. Gregg has authored 21 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Physiology, 6 papers in Psychiatry and Mental health and 5 papers in Cognitive Neuroscience. Recurrent topics in Keith M. Gregg's work include Alzheimer's disease research and treatments (8 papers), Dementia and Cognitive Impairment Research (6 papers) and Anesthesia and Sedative Agents (4 papers). Keith M. Gregg is often cited by papers focused on Alzheimer's disease research and treatments (8 papers), Dementia and Cognitive Impairment Research (6 papers) and Anesthesia and Sedative Agents (4 papers). Keith M. Gregg collaborates with scholars based in United States, United Kingdom and Belgium. Keith M. Gregg's co-authors include Steven L. Shafer, Thomas W. Schnider, Charles F. Minto, Michael Grundman, Enchi Liu, Nick C. Fox, Ronald S. Black, David J. Brooks, Jerome Barakos and Timothy G. Short and has published in prestigious journals such as The Lancet Neurology, Anesthesiology and Journal of Investigative Dermatology.

In The Last Decade

Keith M. Gregg

21 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

2010 536 citations Juha O. Rinne, David J. Brooks et al. The Lancet Neurology profile →

Peers

Countries citing papers authored by Keith M. Gregg

Since Specialization

Citations

This map shows the geographic impact of Keith M. Gregg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Keith M. Gregg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Keith M. Gregg more than expected).

Fields of papers citing papers by Keith M. Gregg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Keith M. Gregg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Keith M. Gregg. The network helps show where Keith M. Gregg may publish in the future.

Co-authorship network of co-authors of Keith M. Gregg

This figure shows the co-authorship network connecting the top 25 collaborators of Keith M. Gregg. A scholar is included among the top collaborators of Keith M. Gregg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Keith M. Gregg. Keith M. Gregg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer’s Disease 2015 ·Journal of Alzheimer s Disease ·Gerald Novak, Nick C. Fox, Shona Clegg, Casper Nielsen, Steven Einstein, Yuan Lü, Iulia Cristina Tudor, Keith M. Gregg, Jianing Di, Peter Collins, Bradley T. Wyman, Eric Yuen, Michael Grundman, H. Robert Brashear, Enchi Liu	38
2	Cognition in MCI and Alzheimer’s Disease: Baseline Data from a Longitudinal Study of the NTB 2014 ·The Clinical Neuropsychologist ·John Harrison, Dorene M. Rentz, Trent McLaughlin, Timothy Niecko, Keith M. Gregg, Ronald S. Black, (unknown), Enchi Liu, Michael Grundman, (unknown)	10
3	P4–417: Incidence and clinical progression of placebo‐treated amyloid‐negative subjects with mild‐to‐moderate Alzheimer's disease (AD): Results from the phase III PET substudies of bapineuzumab and solanezumab 2013 ·Alzheimer s & Dementia ·Stephen Salloway, Reisa A. Sperling, Keith M. Gregg, Peng Yu, Abhinay D. Joshi, Ming‐De Lu, Mark A. Mintun, Michael J. Pontecorvo, Kevin Booth, Bradley T. Wyman, Jia Sun, Karen Sundell, Mark E. Schmidt, Richard Margolin, Daniel Skovronsky, Enchi Liu, Eric Siemers, Robert Brashear	9
4	P1–356: Correlation of brain atrophy with clinical progression in mild‐to‐moderate Alzheimer's disease: Results from the volumetric MRI substudies of two phase III trials with bapineuzumab 2013 ·Alzheimer s & Dementia ·Gerald Novak, Steven Einstein, Yuan Lü, Iulia Cristina Tudor, Keith M. Gregg, Peter Collins, Bradley T. Wyman, Eric Yuen, Casper Nielsen, Michael Grundman, Robert Brashear, Nick C. Fox, Enchi Liu	1
5	P1–352: The rate of clinical progression and brain atrophy is greater with increasing severity of Alzheimer's disease: Results from the volumetric MRI substudies of two phase III trials with bapineuzumab 2013 ·Alzheimer s & Dementia ·Gerald Novak, Steven Einstein, Iulia Cristina Tudor, Keith M. Gregg, Peter Collins, Bradley T. Wyman, Eric Yuen, Casper Nielsen, Michael Grundman, Robert Brashear, Nick C. Fox, Enchi Liu	2
6	O1–06–02: Effect of bapineuzumab on CSF p‐tau and t‐tau in mild‐to‐moderate Alzheimer's disease: Results from two phase III trials in APOE‐ε4 carriers and noncarriers 2013 ·Alzheimer s & Dementia ·Johannes Streffer, Kaj Blennow, Stephen Salloway, Henrik Zetterberg, (unknown), Yuan Lü, (unknown), Peter Collins, Iulia Cristina Tudor, Keith M. Gregg, Scot Styren, Eric Yuen, Michael Grundman, Robert Brashear, Enchi Liu	1
7	Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis 2012 ·The Lancet Neurology ·Reisa A. Sperling, Stephen Salloway, David J. Brooks, Donatella Tampieri, Jerome Barakos, Nick C. Fox, Murray A. Raskind, Marwan N. Sabbagh, Lawrence S. Honig, Anton P. Porsteinsson, Ivan Lieberburg, H. Michael Arrighi, Kristen Morris, Yuan Lü, Enchi Liu, Keith M. Gregg, H. Robert Brashear, Gene G. Kinney, Ronald S. Black, Michael Grundman	366
8	11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study breakdown → 2010 ·The Lancet Neurology ·Juha O. Rinne, David J. Brooks, Martin N. Rossor, Nick C. Fox, Roger Bullock, William E. Klunk, Chester A. Mathis, Kaj Blennow, Jerome Barakos, Aren Okello, (unknown), Enchi Liu, Martin Koller, Keith M. Gregg, Dale Schenk, Ronald S. Black, Michael Grundman	536
9	Using the Time of Maximum Effect Site Concentration to Combine Pharmacokinetics and Pharmacodynamics 2003 ·Anesthesiology ·Charles F. Minto, Thomas W. Schnider, Keith M. Gregg, Thomas K. Henthorn, Steven L. Shafer	107
10	Response Surface Model for Anesthetic Drug Interactions 2000 ·Anesthesiology ·Charles F. Minto, Thomas W. Schnider, Timothy G. Short, Keith M. Gregg, Andrea Gentilini, Steven L. Shafer	255
11	A Technique for Population Pharmacodynamic Analysis of Concentration-Binary Response Data 1997 ·Anesthesiology ·James M. Bailey, Keith M. Gregg	3
12	Preoperative Anxiety and Fear 1996 ·Anesthesia & Analgesia ·Audrey Shafer, (unknown), Keith M. Gregg, (unknown), Peter Kosek	73
13	Role of serotonergic neurotransmission in the hypnotic response to dexmedetomidine, an α2-adrenoceptor agonist 1996 ·European Journal of Pharmacology ·Bradford C. Rabin, (unknown), Keith M. Gregg, Mervyn Maze	11
14	Semilinear Canonical Correlation Applied to the Measurement of the Electroencephalographic Effects of Midazolam and Flumazenil Reversal 1996 ·Anesthesiology ·Thomas W. Schnider, Charles F. Minto, Pierre Fiset, Keith M. Gregg, Steven L. Shafer	12
15	Derivation and Cross-validation of Pharmacokinetic Parameters for Computer-controlled Infusion of Lidocaine in Pain Therapy 1996 ·Anesthesiology ·Thomas W. Schnider, (unknown), William G. Brose, Charles F. Minto, Keith M. Gregg, Steven L. Shafer	31
16	Preoperative Anxiety and Fear 1996 ·Anesthesia & Analgesia ·Audrey Shafer, (unknown), Keith M. Gregg, (unknown), Peter Kosek	62
17	Validation of the Alfentanil Canonical Univariate Parameter as a Measure of Opioid Effect on the Electroencephalogram 1995 ·Anesthesiology ·Pedro L. Gambús, Keith M. Gregg, Steven L. Shafer	32
18	Application of semilinear canonical correlation to the measurement of opioid drug effect 1992 ·Journal of Pharmacokinetics and Biopharmaceutics ·Keith M. Gregg, John R. Varvel, Steven L. Shafer	20
19	Algorithms to rapidly achieve and maintain stable drug concentrations at the site of drug effect with a computer-controlled infusion pump 1992 ·Journal of Pharmacokinetics and Biopharmaceutics ·Steven L. Shafer, Keith M. Gregg	189
20	Epidermal Characteristics Related to Skin Cancer Susceptibility 1982 ·Journal of Investigative Dermatology ·Keith M. Gregg, Jonathan Mansbridge	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact